Sage Therapeutics (STU:SG7) Beginning Cash Position : €76.29 Mil (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Beginning Cash Position?

Sage Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2025 was €76.29 Mil.

Sage Therapeutics's quarterly Beginning Cash Position increased from Sep. 2024 (€92.56 Mil) to Dec. 2024 (€97.85 Mil) but then declined from Dec. 2024 (€97.85 Mil) to Mar. 2025 (€76.29 Mil).

Sage Therapeutics's annual Beginning Cash Position declined from Dec. 2022 (€278.95 Mil) to Dec. 2023 (€150.36 Mil) and declined from Dec. 2023 (€150.36 Mil) to Dec. 2024 (€69.07 Mil).

Sage Therapeutics Beginning Cash Position Historical Data

The historical data trend for Sage Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Beginning Cash Position Chart

Sage Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

Get a 7-Day Free Trial

106.10

1,471.58

278.95

150.36

69.07

Sage Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Beginning Cash Position	Get a 7-Day Free Trial															66.54	163.03	92.56	97.85	76.29

Sage Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Sage Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Sage Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (STU:SG7) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

SAGE:USA SG7:Germany

Address

55 Cambridge Parkway, Cambridge, MA, USA, 02142

Website

https://www.sagerx.com

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Sage Therapeutics Headlines

No Headlines